Genetica

, Volume 104, Issue 2, pp 85–132

The AIDS dilemma: drug diseases blamed on a passenger virus

  • Peter Duesberg
  • David Rasnick
Article

Abstract

Almost two decades of unprecedented efforts in research costing US taxpayers over $50 billion have failed to defeat Acquired Immune Deficiency Syndrome (AIDS) and have failed to explain the chronology and epidemiology of AIDS in America and Europe. The failure to cure AIDS is so complete that the largest American AIDS foundation is even exploiting it for fundraising: ‘Latest AIDS statistics – 0,000,000 cured. Support a cure, support AMFAR.’ The scientific basis of all these unsuccessful efforts has been the hypothesis that AIDS is caused by a sexually transmitted virus, termed Human immunodeficiency virus (HIV), and that this viral immunodeficiency manifests in 30 previously known microbial and non-microbial AIDS diseases. In order to develop a hypothesis that explains AIDS we have considered ten relevant facts that American and European AIDS patients have, and do not have, in common: (1) AIDS is not contagious. For example, not even one health care worker has contracted AIDS from over 800,000 AIDS patients in America and Europe. (2) AIDS is highly non-random with regard to sex (86% male); sexual persuasion (over 60% homosexual); and age (85% are 25–49 years old). (3) From its beginning in 1980, the AIDS epidemic progressed non-exponentially, just like lifestyle diseases. (4) The epidemic is fragmented into distinct subepidemics with exclusive AIDS-defining diseases. For example, only homosexual males have Kaposi's sarcoma. (5) Patients do not have any one of 30 AIDS-defining diseases, nor even immunodeficiency, in common. For example, Kaposi's sarcoma, dementia, and weight loss may occur without immunodeficiency. Thus, there is no AIDS-specific disease. (6) AIDS patients have antibody against HIV in common only by definition–not by natural coincidence. AIDS-defining diseases of HIV-free patients are called by their old names. (7) Recreational drug use is a common denominator for over 95% of all American and European AIDS patients, including male homosexuals. (8) Lifetime prescriptions of inevitably toxic anti-HIV drugs, such as the DNA chain-terminator AZT, are another common denominator of AIDS patients. (9) HIV proves to be an ideal surrogate marker for recreational and anti-HIV drug use. Since the virus is very rare (< 0.3%) in the US/European population and very hard to transmit sexually, only those who inject street drugs or have over 1,000 typically drug-mediated sexual contacts are likely to become positive. (10) The huge AIDS literature cannot offer even one statistically significant group of drug-free AIDS patients from America and Europe. In view of this, we propose that the long-term consumption of recreational drugs (such as cocaine, heroin, nitrite inhalants, and amphetamines) and prescriptions of DNA chain-terminating and other anti-HIV drugs, cause all AIDS diseases in America and Europe that exceed their long-established, national backgrounds, i.e. <95%. Chemically distinct drugs cause distinct AIDS-defining diseases; for example, nitrite inhalants cause Kaposi's sarcoma, cocaine causes weight loss, and AZT causes immunodeficiency, lymphoma, muscle atrophy, and dementia. The drug hypothesis predicts that AIDS: (1) is non-contagious; (2) is non-random, because 85% of AIDS causing drugs are used by males, particularly sexually active homosexuals between 25 and 49 years of age, and (3) would follow the drug epidemics chronologically. Indeed, AIDS has increased from negligible numbers in the early 1980s to about 80,000 annual cases in the early '90s and has since declined to about 50,000 cases (US figures). In the same period, recreational drug users have increased from negligible numbers to millions by the late 1980s, and have since decreased possibly twofold. However, AIDS has declined less because since 1987 increasing numbers of mostly healthy, HIV-positive people, currently about 200,000, use anti-HIV drugs that cause AIDS and other diseases. At least 64 scientific studies, government legislation, and non-scientific reports document that recreational drugs cause AIDS and other diseases. Likewise, the AIDS literature, the drug manufacturers, and non-scientific reports confirm that anti-HIV drugs cause AIDS and other diseases in humans and animals. In sum, the AIDS dilemma could be solved by banning anti-HIV drugs, and by pointing out that drugs cause AIDS – modeled on the successful anti-smoking campaign.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Achard, C., H. Bernard & C. Gagneux, 1909. Action de la morphine sur les proprietes leucocytaires; leuco-diagnostic du morphinisme. Bulletin et Memoires de la Societe Medicale des Hopitanx de Paris 28, 3rd Series: 958–966.Google Scholar
  2. Adams, J., 1989. AIDS: The HIV Myth. St. Martin's Press, New York.Google Scholar
  3. Afrasiabi, R., R.T. Mitsuyasu, K. Schwartz & J.L. Fahey, 1986. Characterization of a distinct subgroup of high-risk persons with Kaposi's sarcoma and good prognosis who present with normal T4 cell number and T4:T8 ratio and negative HTLV-III/LAV serologic results. Am. J. Med. 81: 969–973.PubMedGoogle Scholar
  4. AIDS Weekly, 1995. Government Congressman questions funding for AIDS research. AIDS Weekly (electronic version) May 22.Google Scholar
  5. AIDS Zentrum im Robert Koch Institut, 1996. 120. Bericht des AIDS Zentrum im Robert Koch Institut. AIDS Forschung 11: 47–56.Google Scholar
  6. AIDS-Zentrum im Robert Koch-Institut, 1997. 125. Bericht des AIDS-Zentrum im Robert Koch-Institut ueber aktuelle epidemiologische Daten. AIDS/HIV (Quartalsbericht I/97).Google Scholar
  7. Alcabes, P., E.E. Schoenbaum & R.S. Klein, 1993. Correlates of the rate of decline of CD4+ lymphocytes among injection drug users infected with the human immunodeficiency virus. Am J. Epidemiol. 137(9): 989–1000.PubMedGoogle Scholar
  8. Alroomi, L.G., J. Davidson, T.J. Evans, P. Galea & R. Howat, 1988. Maternal narcotic abuse and the newborn. Arch. Dis. Child. 63: 81–83.PubMedGoogle Scholar
  9. Altman, L.K., 1984. Researchers believe AIDS virus is found. New York Times, April 24, p C1, C3.Google Scholar
  10. Anderson, W., 1987. Drug Smuggling. U.S. General Accounting Office, Washington, DC.Google Scholar
  11. Aral, S.O. & K.K. Holmes, 1991. Sexually transmitted diseases in the AIDS era. Sci. Am. 264:(Feb.) 62–69.Google Scholar
  12. Archer, C.B., M.F. Spittle & N.P. Smith, 1989. Kaposi's sarcoma in a homosexual — 10 years on. Clin. Exper. Dermatol. 14: 233–236.Google Scholar
  13. Ascher, M.S., H.W. Sheppard, W. Winkelstein Jr & E. Vittinghoff, 1993. Does drug use cause AIDS? Nature (London) 362: 103–104.Google Scholar
  14. Ascher, M.S., H.W. Sheppard & W. Winkelstein Jr., 1995a. AIDS-associated Kaposi's sarcoma (letter). Science 267: 1080.PubMedGoogle Scholar
  15. Ascher, M.S., H.W. Sheppard & W. Winkelstein, 1995b, AIDS Data. Science 268: 351–352.Google Scholar
  16. Ashe, A. & A. Rampersad, 1993. Days of Grace. Alfred A. Knopf, New York.Google Scholar
  17. Associated Press, 1995. Study Finds Ex-Smokers Still Risk Lung Cancer. San Francisco Chroniele, May 23, p. A5.Google Scholar
  18. Associated Press, 1997. S53.7 billion spent on illegal drugs in '95. San Francisco Chronicle, November 10, p. A6.Google Scholar
  19. Auerbach, D.M., W.W. Darrow, H.W. Jaffe & J.W. Curran, 1984. Cluster of cases of the Acquired Immune Deficiency Syndrome patients linked by sexual contact. Am. J. Med. 76: 487–492.PubMedGoogle Scholar
  20. Ayers, K.M., W.E. Tucker, G. Hajian & P. de Miranda, 1996. Nonclinical toxicology studies with zidovudine: acute, subacute, and chronic toxicity in rodents, dogs, and monkeys, Fundamental and Applied Toxicology 32: 129–139.Google Scholar
  21. Aylward, E.H., A.M. Butz, N. Hutton, M.L. Joyner & J.W. Vogelhut, 1992. Cognitive and motor development in infants at risk for human immunodeficiency virus. Am. J. Dis. Child. 146(2): 218–222.PubMedGoogle Scholar
  22. Bacellar, H., A. Munoz, E.N. Miller, B.A. Cohen, D. Besley, O.A. Selnes, J.T. Becker & J.C. McArthur, 1994. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985–1992. Neurology 44: 1892–1900.PubMedGoogle Scholar
  23. Baldwin, G.C., D.P. Tashkin, D.M. Buckley, A.N. Park, S.M. Dubinett & M.D. Roth, 1997. Marijuana and cocaine impair alveolar macrophage function and cytokine production. American Journal of Respiratory and Critical Care Medicine 156: 1606–1613PubMedGoogle Scholar
  24. Baldwin, G.C., M.D. Roth & D.P. Tashkin, 1998. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol 83(1–2): 139–147.Google Scholar
  25. Balter, M., 1997. How does HIV overcome the body's T cell bodyguards? Science 278: 1399–1400.PubMedGoogle Scholar
  26. Barre-Sinoussi, F., J.C. Chermann, F. Rey et al., 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868–871.PubMedGoogle Scholar
  27. Bennett, A. & A. Sharpe, 1996. AIDS fight is skewed by federal campaign exaggerating risks. Wall Street Journal, May 1, p. 1, A6.Google Scholar
  28. Beral, V., T.A. Peterman, R.L. Berkelman & H.W. Jaffe, 1990. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 335: 123–128.PubMedGoogle Scholar
  29. Bergling, T., 1997. All methed up, ‘doing crystal meth will lift you up until you break’. Genre, October, p. 45–47, 88.Google Scholar
  30. Bessen, L.J., J.B. Greene, E. Louie, L.E. Seitzman & H. Weinberg, 1988. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. N. Engl. J. Med. 318: 708.PubMedGoogle Scholar
  31. Bethell, T., 1996. AIDS and poppers, pp 315–323 in AIDS: Virus or Drug-Induced?, edited by P. Duesberg. Kluwer Academic Publishers, Dordrecht, Netherlands.Google Scholar
  32. Blanche, S., M.-J. Mayaux, C. Rouzious et al., 1994. Relation of the Course of HIV Infection in Children to the Severity of the Disease in their Mothers at Delivery. The New England Journal of Medicine 330(5): 308–312.PubMedGoogle Scholar
  33. Blanche, S., C. Rouzioux, M.L.G. Moscato et al., 1989. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. N. Engl. J. Med. 320: 1643–1648.PubMedGoogle Scholar
  34. Blattner, W.A., R.C. Gallo & H.M. Temin, 1988. HIV causes AIDS. Science 241: 514–515.Google Scholar
  35. Booth, W., 1988. A rebel without a cause for AIDS. Science 239: 1485–1488.PubMedGoogle Scholar
  36. Bradbury, J., 1998. Is the honeymoon over for Viagra? Lancet 351: 1635.Google Scholar
  37. Braeu, N., H.L. Leaf, R.L. Wieczorck & D.M. Margolis, 1997. Severe hepatitis in three AIDS patients treated with Indinavir. Lancet 349: 924–925.Google Scholar
  38. Braun, M.M., B.I. Truman, B. Maguire, G.T. Di Ferdinando, Jr., G. Wormser, R. Broaddus & D. L. Morse, 1989. Increasing incidence of tuberculosis in a prison inmate population, associated with HIV-infection. J. Am. Med. Assoc. 261: 393–397.Google Scholar
  39. Breckenridge, A., V. Kitchen & J. Derbyshire, 1997. Antiretroviral drug trials. Science 276(5318): 1481–1482.PubMedGoogle Scholar
  40. Bregman, D.J. & A.D. Langmuir, 1990. Farr's law applied to AIDS projections. J. Am. Med. Assoc. 263: 50–57.Google Scholar
  41. Brettle, R.P., 1996. Clinical features of drug use and drug use related to HIV. Int. J. STD & AIDS 7: 151–165.Google Scholar
  42. Briggs, J.H., C.G. McKerron, R.L. Souhami, D.J.E. Taylor & H. Andrews, 1967. Severe systemic infections complicating ‘mainline’ heroin addiction. Lancet ii: 1227–1231.Google Scholar
  43. Brown, S.M., B. Stimmel, R.N. Taub, S. Kochwa & R.E. Rosenfield, 1974. Immunologic dysfunction in heroin addicts. Arch. Intern. Med. 134: 1001–1006.PubMedGoogle Scholar
  44. Brudney, K. & J. Dobkin, 1991. Resurgent tuberculosis in New York City. Am. Rev. Respir. Dis. 144: 744–749.Google Scholar
  45. Buchbinder, S.P., M.H. Katz, N.A. Hessol, P.M. O'Malley & S.D. Holmberg, 1994. Long-term HIV-1 infection without immunologic progression. AIDS 8(8): 1123–1128.PubMedGoogle Scholar
  46. Bureau of Justice Statistics, 1988. Special Report — Drug Law Violators, 1980–1986. U.S. Department of Justice, Washington, DC.Google Scholar
  47. Bureau of Justice Statistics, 1991. Catalog of Federal Publications on Illegal Drug and Alcohol Abuse. U.S. Department of Justice, Washington, DC.Google Scholar
  48. Burcau of Justice Statistics, 1992. Drugs, crime, and the justice system, U.S. Dept. of Justice, Washington, DC.Google Scholar
  49. Cairns, J., 1978. Cancer: Science and Society. W.H. Freeman and Company, San Francisco.Google Scholar
  50. Cairns, J., 1997. Matters of Life and Death; perspectives on public health, molecular biology, cancer, and the prospects for the human race. Princeton University Press, Princeton, New Jersey.Google Scholar
  51. Callen, M., 1990. Surviving AIDS. HarperPerennial, New York.Google Scholar
  52. Carman, J., 1998. ‘Frontline’ asks if drug war is going to pot. San Francisco Chronicle, April 28, p. E1.Google Scholar
  53. Centers for Disease Control, 1981. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men — New York City and California. Morbidity and Mortality Weekly Reports 30: 305–308.Google Scholar
  54. Centers for Disease Control, 1982. Update on acquired immune deficiency syndrome (AIDS) — United States. Morbid. Mortal. Weekly Rep. 31: 507–514.Google Scholar
  55. Centers for Disease Control, 1983. An Evaluation of the Immunotoxic Potential of Isobutyl Nitrite. Morbid. Mortal Weekly Rep. 32(September 9): 457–458, 464.Google Scholar
  56. Centers for Disease Control, 1985. Revision of the case definition of AIDS for national reporting — United States. Morb. Mortal. Weekly Rep. 34: 373–375.Google Scholar
  57. Centers for Disease Control (eds), 1986. Reports on AIDS published in the Morbidity and Mortality Weekly Report, June 1981 through February 1986. U.S. Dept. of Health and Human Services, National Technical Information Service, Springfield, VA.Google Scholar
  58. Centers for Disease Control, 1987. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. J. Am. Med. Assoc. 258: 1143–1154.Google Scholar
  59. Centers for Disease Control, 1994. Hetereosexually acquired AIDS —United States, 1993. Morb. Mortal. Weekly Rep. 43(9): 155–160.Google Scholar
  60. Centers for Disease Control, 1995. National HIV serosurveillance summary; update 1993. US Dept. HHS.Google Scholar
  61. Centers for Disease Control and Prevention, 1992. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb. Mort. Weekly Rep. 41(No.RR17): 1–19.Google Scholar
  62. Centers for Disease Control and Prevention, 1995. U.S. HIV and AIDS cases reported through December 1995. HIV/AIDS Surveillance Report 7(2): 1–39.Google Scholar
  63. Centers for Disease Control and Prevention, 1996. U.S. HIV and AIDS cases reported through December 1996. HIV/AIDS Surveillance Report 8(2): 1–39.Google Scholar
  64. Centers for Discase Control and Prevention, 1997. U.S. HIV and AIDS cases reported through December 1997; Year-end edition. 9:(2) 1–43.Google Scholar
  65. Chamberland, M. E., & J. W. Curran, 1990. Epidemiology and prevention of AIDS and HIV infection, pp. 1029–1046 in Principles and practice of infectious diseases edited by G.L. Mandel, R.G. Douglas & J.E. Benett, Churchill Livingstone, New York, Edinburgh, London.Google Scholar
  66. Chiu, D. & P. Duesberg, 1995. The Toxicity of Aziodothymidine (AZT) on Human and Animal Cells in Culture at Concentrations Used for Antiviral Therapy. Genetica 95: 103–109.PubMedGoogle Scholar
  67. Chorba, T.L., R.C. Holman, T.W. Strine, M.J. Clarke & B.L. Evatt, 1994. Changes in longevity and causes of death among persons with hemophilia A. Am. J. Hematol. 45: 112–121.PubMedGoogle Scholar
  68. Clinton, W. & The White House, 1996. The National Drug Control Strategy: 1996. The White House, Washington, DC.Google Scholar
  69. Cohen, J., 1993. HHS: Gallo guilty of misconduct. Science 259: 168–170.PubMedGoogle Scholar
  70. Cohen, J., 1994a. The Duesberg Phenomenon. Science 266: 1642–1649.PubMedGoogle Scholar
  71. Cohen, J., 1994b. Is a new virus the cause of KS? Science 266: 1803–1804.PubMedGoogle Scholar
  72. Cohen, J., 1995. Researchers air alternative views on how HIV kills cells. Science 269(25 August): 1044–1045.Google Scholar
  73. Cohen, J., 1997a. Advances painted in shades of gray at a D.C. conference. Science 275: 615–616.PubMedGoogle Scholar
  74. Cohen, J., 1997b. The media's love affair with AIDS research: Hope vs. hype. Science 275: 298–299.Google Scholar
  75. Cohen, S.S., 1987. Antiretroviral therapy for AIDS. N. Engl. J. Med. 317: 629.PubMedGoogle Scholar
  76. Connor, E.M., R.S. Sperling, R. Gelber et al., 1994. Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 With Zidovudine Treatment. New Engl. J. Med. 331(18): 1173–1180.PubMedGoogle Scholar
  77. Cotton, P., 1994. Trial Halted After Drug Cuts Maternal HIV Transmission Rate By Two Thirds. J. Am. Med. Assoc. 271(11): 807.Google Scholar
  78. Courtwright, D.T., 1982. Dark Paradisc: opiate addiction in America before 1940. Harvard University Press, Cambridge, MA.Google Scholar
  79. Craddock, M., 1996. A critical appraisal of the Vancouver men's study; does it refute the drugs/AIDS hypothesis? pp. 105–110 in AIDS: Virus or drug-induced edited by P.H. Duesberg. Kluwer Academic Publishers, Dordrecht, Netherlands.Google Scholar
  80. Cronkite, E.P. & J. Bullis, 1990. In vivo toxicity of 3′-azido-2′,3′-dideoxythymidine (AZT) on CBA/Ca mice. International Journal of Cell Cloning 8: 332–345.PubMedGoogle Scholar
  81. Culver, K.W., A.J. Ammann, J.C. Patridge, D.F. Wong, D.W. Wara & M.J. Cowan, 1987. Lymphocyte abnormalities in infants born to drug-abusing mothers. J. Pediatr. 111: 230–235.PubMedGoogle Scholar
  82. Curran, J.W., M.W. Morgan, A.M. Hardy, H.W. Jaffe, W.W. Darrow & W.R. Dowdle, 1985. The epidemiology of AIDS: current status and future prospects. Science 229: 1352–1357.PubMedGoogle Scholar
  83. Dalakas, M.C., I. Illa, G.H. Pezeshkpour, J.P. Laukaitis, B. Cohen & J.L. Griffin, 1990. Mitochondrial myopathy caused by long-term zidovudine therapy. N. Engl. J. Med. 322: 1098–1105.PubMedGoogle Scholar
  84. Darby, S.C., D.W. Ewart, P.L.F. Giangrande, P.J. Dolin, R.J.D. Spooner, C.R. Rizza & on behalf of the UK Haemophilia Centre Directors' Organisation, 1995. Mortality before and after HIV infection in the complete UK population of haemophiliaes (letter). Nature (London) 377(7 September): 79–82.Google Scholar
  85. Darrow, W.W., D.F. Echenberg, H.W. Jaffe, P.M. O'Malley, R.H. Byers, J.P. Getchell & J.W. Curran, 1987. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am. J. Publ. Health 77: 479–483.Google Scholar
  86. Dax, E.M., J.E. Nagel, W.R. Lange, W.H. Adler & J.H. Jaffe, 1988. Effects of nitrites on the immune system of humans. pp. 75–59 in Health hazards of nitrite inhalants, NIDA Res. Monograph 83, edited by H.W. Haverkos & J.A. Dougherty. Dept. Health & Human Services, Washington, DC.Google Scholar
  87. Des Jarlais, D., S. Friedman, M. Marmor et al., 1987. Development of AIDS, HIV seroconversion, and potential cofactors for T4 cell loss in a cohort of intravenous drug users. AIDS 1: 105–111.PubMedGoogle Scholar
  88. Des Jarlais, D.C., S.R. Friedman & W. Hopkins, 1988. Risk reduction of the acquired immunodeficiency syndrome among intravenous drug users, pp. 97–109 in AIDS and IV Drug Abusers: Current Perspectives, edited by R.P. Galea, B.F. Lewis & L. Baker. National Health Publishing, Owings Mills, MD, USA.Google Scholar
  89. Deutsche Hauptstelle gegen die Suchtgefahren, 1996. Jahrbuch Such '97. Neuland Verlag, Geesthacht, Germany.Google Scholar
  90. Dismukes, W. E., A. W. Karchmer, R. F. Johnson & W. J. Dougherty, 1968. Viral hepatitis associated with illcit parenteral use of drugs. J. Am. Med. Assoc. 206: 1048–1052.Google Scholar
  91. Donahoe, R.M., C. Bueso-Ramos, F. Donahoe, J.J. Madden, A. Falek, J.K.A. Nicholson & P. Bokos, 1987. Mechanistic implications of the findings that opiates and other drugs of abuse moderate T-cell surface receptors and antigenic markers. Ann. N.Y. Acad. Sci. 496: 711–721.PubMedGoogle Scholar
  92. Douglas, R.G.J., 1990. Antimicrobial Agents, p. 1182 in The Pharmacological Basis of Therapeutics, edited by Alfred & Goodman & Gilman et al. Pergamon Press, New York.Google Scholar
  93. Drotman, D.P. & H. Haverkos, 1992. What Causes Kaposi's Sarcoma? Inquiring Epidemiologists Want to Know. Epidemiology 3(3): 191–193.PubMedGoogle Scholar
  94. Drotman, D.P., T.A. Peterman & A.E. Friedman-Kien, 1995. Kaposi's sarcoma. How can epidemiology help find the cause? Dermatoepidemiology 13(3): 575–582.Google Scholar
  95. Drug Strategies, 1995. Keeping score; What We Are Getting for Our Federal Drug Control Dollars. Drug Strategies, Washington, DC.Google Scholar
  96. Drug Strategies, 1996. Keeping Score, p. 1–33.Google Scholar
  97. Duesberg, P.H., 1987. Retroviruses as carcinogens and pathogens: expectations and reality. Cancer Res. 47: 1199–1220.PubMedGoogle Scholar
  98. Duesberg, P.H., 1988. HIV is not the cause of AIDS. Science 241: 514–516.PubMedGoogle Scholar
  99. Duesberg, P.H., 1989. Human immunodeficiency virus and acquired immunodeficiency syndrome: Correlation but not causation. Proc. Natl. Acad. Sci. USA 86: 755–764.PubMedGoogle Scholar
  100. Duesberg, P.H., 1991. AIDS epidemiology: inconsistencies with human immunodeficiency virus and with infectious disease. Proc. Natl. Acad. Sci. USA 88(Feb.): 1575–1579.Google Scholar
  101. Duesberg, P.H., 1992a. AIDS acquired by drug consumption and other noncontagious risk factors. Pharmacology & Therapeutics 55: 201–277.Google Scholar
  102. Duesberg, P.H., 1992b, HIV, AIDS, and zidovudine. Lancet 339: 805–806.Google Scholar
  103. Duesberg, P.H., 1993a. Aetiology of AIDS. Lancet 341: 1544.PubMedGoogle Scholar
  104. Duesberg, P.H., 1993b. Can epidemiology determine whether drugs or HIV cause AIDS? AIDS-Forschung 12: 627–635.Google Scholar
  105. Duesberg, P.H., 1993c. HIV and AIDS. Science 260: 1705.PubMedGoogle Scholar
  106. Duesberg, P.H., 1993d. HIV and the aetiology of AIDS. Lancet 341: 957–958.PubMedGoogle Scholar
  107. Duesberg, P.H., 1993e. The HIV gap in national AIDS statistics. Biotechnology 11: 955–956.PubMedGoogle Scholar
  108. Duesberg, P.H., 1994. Infectious AIDS — stretching the germ theory beyond its limits. Int. Arch. Allergy Immunol. 103: 131–142.Google Scholar
  109. Duesberg, P.H., 1995a. AIDS Data. Science 268(21 April): 350–351.Google Scholar
  110. Duesberg, P.H., 1995b. ‘The Duesberg-Phenomenon’: Duesberg and Other Voices (letter). Science 267: 313.PubMedGoogle Scholar
  111. Duesberg, P.H., 1995c. Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV. Genetica 95: 51–70.PubMedGoogle Scholar
  112. Duesberg, P.H., 1995d. Is HIV the cause of AIDS? (letter). Lancet 346(November 18): 1371–1372.Google Scholar
  113. Duesberg, P.H., 1996a. Commentary: non-HIV hypotheses must be studied more carefully. Br. Med. J. 312(27 January): 210–211.Google Scholar
  114. Duesberg, P.H., 1996b. Duesberg's questions. C&EN (March 25) 4, 40.Google Scholar
  115. Duesberg, P.H., 1996c. How much longer can we afford the AIDS virus monopoly? pp. 241–270 in AIDS: virus-or drug induced?, edited by P. Duesberg. Kluwer, Dordrecht, Netherlands.Google Scholar
  116. Duesberg, P.H., 1996d. Inventing the AIDS Virus. Regnery Publishing Inc., Washington.Google Scholar
  117. Duesberg, P.H., & H. Bialy, 1996. Duesberg and the right of reply according to Maddox-Nature. pp. 111–125 in AIDS: virus-or Drug-Induced?, 5, edited by P. H. Duesberg. Kluwer Academic Publishers, Dordrecht/Boston/London.Google Scholar
  118. Duesberg, P.H., & D. Rasnick, 1997. The drug AIDS hypothesis. Continuum (London) 4Supplement (5): 1–24.Google Scholar
  119. Durack, D.T., 1981. Opportunistic infections and Kaposi's sarcoma in homosexual men. The New England Journal of Medicine 305(24): 1465–1467.PubMedGoogle Scholar
  120. Ellison, B. J., A. B. Downey & P. H. Duesberg, 1996. HIV as a surrogate marker for drug-use: a re-analysis of the San Francisco Men's Health Study. pp. 97–194 in AIDS: virus-or drug induced?, edited by P.H. Duesberg. Kluwer Academic Publishers, Dordrecht, The Netherlands.Google Scholar
  121. Espinoza, P., I. Bouchard, C. Buffet, V. Thiers, J. Pillot & J.P. Etienne, 1987. High prevalence of infection by hepatitis B virus and HIV in incarcerated French drug addicts. Gastroenterologie Clinique et Biologique 11(4): 288–292.PubMedGoogle Scholar
  122. Ettinger, N.A., & R.J. Albin, 1989. A review of the respiratory effects of smoking cocaine. Am. J. Med. 87: 664–668.PubMedGoogle Scholar
  123. European Collaborative Study, 1991. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 337: 253–260.Google Scholar
  124. Evans, A.S. (eds), 1982. Viral Infection of Humans: Epidemiology and Control. Plenum Medical Book Company, New York/London.Google Scholar
  125. Evans, A.S. & H.A. Feldman (eds), 1982. Bacterial Infections of Humans: epidemiology and Control. Plenum Medical Book Company, New York/London.Google Scholar
  126. Evenson, L. & S. Whiting, 1996. Heroin's in Fashion — and Death Statistics Prove It. San Francisco Chronicle, Jul 30, p A1–A8.Google Scholar
  127. Farber, C., 1994. AIDS: Words from the Front. SPIN, April, p. 81–83, 102.Google Scholar
  128. Fenner, F., B.R. McAuslan, C.A. Mims, J. Sambrook & D.O. White, 1974. The Biology of Animal Viruses. Academic Press, Inc., New York.Google Scholar
  129. Fettner, A.G. & W.A. Check, 1985. The Truth about AIDS: Evolution of an Epidemic. Holt, Rinehart and Wilson, New York.Google Scholar
  130. Fiala, C., 1998. AIDS in Africa: dirty tricks. New African, p. 36–38.Google Scholar
  131. Fiala, C. & P.M. Lingens, 1997. Leben wir gefaehrlich? F. Deuticke Verlagsgesellschaft, Wien, Austria.Google Scholar
  132. Fietz, M., 1997. Haschisch an der Spitze; SPD: Mildere Strafen fuer Drogenhaendler. Die Welt, Jan. 8, p. 1,2.Google Scholar
  133. Fineberg, H. V., 1988. The social dimensions of AIDS. Sci. Am., p. 128–134.Google Scholar
  134. Finnegan, L.P., J.M. Mellot, L.R. Williams & R.J. Wapner, 1992. Perinatal exposure to cocaine: Human studies. pp. 391–409 in Cocaine: Pharmacology, Physiology and Clinical Strategies edited by J.M. Lakoski, M.P. Galloway & F.J. White. CRC Press. Boca Raton, FL.Google Scholar
  135. Firooznia, H., G. Seliger & R. M. Abrams, 1973. Disseminated extrapulmonary tuberculosis in association with heroin addiction. Radiology 109: 291–296.PubMedGoogle Scholar
  136. Fischl, M.A., D.D. Richman, D. M. Causey et al., 1989. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. J. Am. Med. Assoc. 262(17): 2405–2410.Google Scholar
  137. Fischl, M.A., D.D. Richman, M.H. Grieco et al., 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317: 185–191.PubMedGoogle Scholar
  138. Flanagan, T. J. & K. Maguire, 1989. Sourcebook of Criminal Justice Statistics (1989) — Bureau of Justice Statistics NCJ-124224. U.S. Department of Justice, U.S. Government Printing Office, Washington, DC, USA.Google Scholar
  139. Fogelman, I., L. Lim, R. Bassett, P. Volberding, M.A. Fischl, K. Stanley, D.J. Cotton & for the AIDS Clinical Trials Group, 1994. Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type 1 clinical trials. Journal of Acquired Immune Deficiency Syndromes 7: 1057–1063.PubMedGoogle Scholar
  140. Francis, D. P., J. W. Curran & M. Essex, 1983. Epidemic acquired immune deficiency syndrome: Epidemiologic evidence for a transmissible agent. J. Natl. Cancer Inst. 71:(1) 1–4.PubMedGoogle Scholar
  141. Freeman, E., 1996. HIV does not cause AIDS. Health Quest, Fall 1996, p. 35–49.Google Scholar
  142. Freestone, D.S., 1992. Zidovudine. Lancet 339: 626.PubMedGoogle Scholar
  143. Freiman, J.P., K.E. Helfert, M.R. Hamrell & D.S. Stein, 1993. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 7: 379–385.PubMedGoogle Scholar
  144. Fricker, H.S. & S. Segal, 1978. Narcotic addiction, pregnancy, and the newborn. Am. J. Dis. Child. 132: 360–366.PubMedGoogle Scholar
  145. Friedman, L.N., M.T. Williams, T.P. Singh & T.R. Frieden, 1996. Tuberculosis, AIDS, and death among substance abusers on Welfare in New York City. N. Engl. J. Med. 334(13): 828–833.PubMedGoogle Scholar
  146. Friedman-Kien, A.E., B.R. Saltzman, Y. Cao, M.S. Nestor, M. Mirabile, J.J. Li & T.A. Peterman, 1990. Kaposi's sarcoma in HIV-negative homosexual men. Lancet 335: 168–169.PubMedGoogle Scholar
  147. Gallagher, J., 1997. Slipping up; unsafe sex is on the rise — and the new AIDS drugs are only one of the culprits. The Advocate, July 8, p. 33–34.Google Scholar
  148. Gallo, R. C., 1991....and his response. Nature (London) 351: 358.Google Scholar
  149. Gallo, R.C., S.Z. Salahuddin, M. Popovic et al., 1984. Frequent detection and isolation of cytopathic retrovirus (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500–503.PubMedGoogle Scholar
  150. Gallo, R.C., P.S. Sarin, E.P. Gelmann, M. Robert-Guroff & E. Richardson, 1983. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220: 865–867.PubMedGoogle Scholar
  151. Ganem, D., 1997. KSHV and Kaposi's sarcoma: the end of the beginning? Cell 91: 157–160.PubMedGoogle Scholar
  152. Garay, S.M., M. Belenko, E. Fazzini & R. Schinella, 1987. Pulmonary manifestations of Kaposi's sarcoma. Chest 91: 39–43.PubMedGoogle Scholar
  153. Garrett, L., 1998. Weird symptoms seen with new AIDS drugs. San Francisco Chronicle, February 5, p. A7.Google Scholar
  154. Geller, S.A. & B. Stimmel, 1973. Diagnostic confusion from lymphatic lesions in heroin addicts. Ann. Intern. Med. 78: 703–705.PubMedGoogle Scholar
  155. Gibbons, J., 1996. Drugs & Us. Gay Times (London), September, p. 17–37.Google Scholar
  156. Gill, P.S., B. Akli, P. Coletti, M. Rarick, C. Louriero, M. Bernstein-Singer, M. Krailo & L.A.M., 1989. Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. Am. J. Med. 87: 57–61.PubMedGoogle Scholar
  157. Gill, P.S., M. Rarick, R.K. Byrnes, D. Causey, C. Loureiro & A.M. Levinc, 1987. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 107: 502–505.PubMedGoogle Scholar
  158. Goedert, J.J., A.R. Cohen, C.M. Kessler, S. Eichinger, S.V. Seremetis, C.S. Rabkin, F.J. Yellin, P.S. Rosenberg & L.M. Aledort, 1994. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Lancet 344: 791–792.PubMedGoogle Scholar
  159. Goedert, J.J., C.Y. Neuland, W.C. Wallen, M.H. Greene, D.L. Mann, C. Murray, D.M. Strong, J.F. Fraumeni, Jr. & W.A. Blattner, 1982. Amyl nitrite may alter T lymphocytes in homosexual men. Lancet i: 412–416.Google Scholar
  160. Gorard, D.A. & R.J. Guilodd, 1988. Necrotising myopathy and zidovudine. Lancet i: 1050.Google Scholar
  161. Gottlieb, M.S., H.M. Schanker, P.T. Fan, A. Saxon, J.D. Weisman & J. Pozalski, 1981a. Pneumocystis pneumonia — Los Angeles. Morbidity and Mortality Weekly Reports 30: 250–252.Google Scholar
  162. Gottlieb, M.S., R. Schroff, H.M. Schanker, J.D. Weisman, P.T. Fan, R.A. Wolf & A. Saxon, 1981b. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305: 1425–1431.PubMedGoogle Scholar
  163. Grcenblatt, R.M., H. Hollander, J.R. McMaster & C.J. Henke, 1991. Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments. Journal of Acquired Immune Deficiency Syndromes 4(2): 136–143.Google Scholar
  164. Grossman, S.J., N. Reinfoed, R.S. Eydelloth, D.W. Alberts, P.F. Smith & D.H. Patrick, 1997. Hepatotoxicity of an HIV protease inhibitor in dogs and rats. Toxicol. Appl. Pharmacol. 146(1): 40–52.PubMedGoogle Scholar
  165. Grubman, S., E. Gross, N. Lerner-Weiss, M. Hernandez, G.D. McSherry, L.G. Hoyt, M. Boland & J.M. Oleske, 1995. Older Children and Adolescents Living with Perinatally Acquired Human Immunodeficiency Virus Infection. Pediatrics 95(5): 657–663.PubMedGoogle Scholar
  166. Gutknecht, G., 1995. Letter of Congressman Gil Gutknecht to Dr. Anthony Fauci, director of the National Institute of Allergies and Infectious Diseases, in Inventing The AIDS Virus by Peter Duesberg, A. Regnery, Washington, DC, 1996.Google Scholar
  167. Hall, C.T., 1996. AIDS advances boost drugmaker. San Francisco Chronicle, August 1, p. E1–E2.Google Scholar
  168. Hallauer, J. F. & S. Kupsch, 1997. Die HIV/AIDS-Pandemie. pp. 1–32, in AIDS und die Vorstadien edited by J. L'age-Stehr & E.B. Helm. Springer Verlag, Berlin, Heidelberg.Google Scholar
  169. Harden, V.A., 1992. Koch's postulates and the etiology of AIDS: an historical perspective. Hist. Phil. Life Sci. 14: 249–269.Google Scholar
  170. Harris, P.D. & R. Garret, 1972. Susceptibility of addicts to infection and neoplasia. New. Engl. J. Med. 287: 310.PubMedGoogle Scholar
  171. Haverkos, H. W., 1988. Kaposi's sarcoma and nitrite inhalants, pp. 165–172 in Psychological, Neuropsychiatric and Substance Abuse Aspects of AIDS, edited by T.P. Bridge, H. Heather & M. Johnson, Raven Press, New York.Google Scholar
  172. Haverkos, H.W., 1990. Nitrite inhalant abuse and AIDS-related Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. 3:Supplement 1, S47–S50.PubMedGoogle Scholar
  173. Haverkos, H.W. & J. Dougherty, 1988a. Health hazards of nitrite inhalants. Am. J. Med. 84: 479–482.PubMedGoogle Scholar
  174. Haverkos, H.W. & J.A. Dougherty (eds), 1988b. Health Hazards of Nitrite Inhalants. 83, US. Dept. Health & Human Services, Washington, DC.Google Scholar
  175. Haverkos, H.W. & D.P. Drotman, 1995. NIDA Technical Review: Nitrite Inhalants. NIDA, Washington, DC & CDC, Atlanta, GA, unpublished.Google Scholar
  176. Haverkos, H.W., D.P. Drotman & D. Hanson, 1994. Surveillance for AIDS-related Kaposi's sarcoma (KS): update. NIDA/CDC, Rockville, MD/Atlanta, GA, May.Google Scholar
  177. Haverkos, H.W., P.F. Pinsky, D.P. Drotman & D.J. Bregman, 1985. Disease manifestation among homosexual men with acquired immunodeficiency syndrome: a possible role of nitrites in Kaposi's sarcoma. J. Sex. Trans. Dis. 12: 203–208.Google Scholar
  178. Hayes, T., R. Altman, A. Akili-Obika, J.W. Buehler, S.J. Costa, J.K. Beil, L.G. Moore, J.W. Massey & N.M. Williams, 1994. HIV-related deaths from selected infectious diseases among persons without AIDS in New Jersey. Journal of Acquired Immune Deficiency Syndromes 7: 1074–1078.PubMedGoogle Scholar
  179. Heitz, D., 1997. Men behaving badly; the recklessness of the 1970s and early '80s has reappeared on the party circuit, where gay men are indulging in illicit drugs and wild sex with increasing abandon. The Advocate, July 8, p. 26–29.Google Scholar
  180. Helbert, M., T. Fletcher, B. Peddle, J.R.W. Harris & A.J. Pinching, 1988. Zidovudine-associated myopathy. Lancet ii: 689–690.Google Scholar
  181. Heresi, G.P., E. Caceres, J.T. Atkins, J. Rueben & M. Doyle, 1997. Pneumocystis carinii pneumonia in infants who were exposed to human immunodeficiency virus but were not infected: an exception to the AIDS Surveillance case definition. Clinical Infectious diseases 25: 739–740.PubMedGoogle Scholar
  182. Hitchcock, M.J.M., 1991. Review: Antiviral portrait series, Number 1; 2′,3′-Didehydro-2′,3′-dideoxythymidine (D4T), an anti-HIV agent. Antiviral Chem. Chemother. 2(3): 125–132.Google Scholar
  183. Hodgkinson, N., 1996. AIDS: the failure of contemporary science. Fourth Estate, London, UK.Google Scholar
  184. Holding, R. & W. Carlsen, 1998. Epidemic ravages caregivers. San Francisco Chronicle, 13 April, p. 1,A6–A8.Google Scholar
  185. Holtermann, S., 1997. Glueck aus der Pille? First, May, p. 16–17.Google Scholar
  186. Horton, R., 1995. Will Duesberg now concede defeat? Lancet 346: 656.PubMedGoogle Scholar
  187. Horwitz, J.P., J. Chua & M. Noel, 1964. Nucleosides. V. The monomesylates of 1-(2′-deoxy-beta-D-lyxofuranosyl)thymidine. J. Org. Chem. 29: 2076.Google Scholar
  188. Hudson, R. & S. Davidson, 1986. Rock Hudson — his story. William Morrow & Co., New York.Google Scholar
  189. Hughes, M.D., D.S. Stein, H.M. Gundacker, F.T. Valentine, J.P. Phair & P.A. Volberding, 1994. Within-Subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: Implications for patient Monitoring. J. Infectious Diseases 169: (January) 28–36.Google Scholar
  190. Ineichen, H., 1996. Ausgeschnüffelt? aK (Switzerland), October November, p. 18–19.Google Scholar
  191. Inoue, T., E.P. Cronkite, Y. Hirabayashi, J.E. Bullis, H. Mitsui & T. Umemura, 1997. Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia. Leukemia 11: 123–127.PubMedGoogle Scholar
  192. Institute of Medicine & National Academy of Sciences, 1986. Confronting AIDS. National Academy Press, Washington, DC.Google Scholar
  193. Irwin, D.H. & L.D. Kaplan, 1993. Pulmonary manifestations of acquired immunodeficiency syndrome-associated malignancies. Seminars in Respiratory Infections 8: 139–148.PubMedGoogle Scholar
  194. Jacobson, M.A., P. de Miranda, S.M. Gordon, M.R. Blum, P. Volberding & J. Mills, 1988. Prolonged pancytopenia due to combined ganciclovir and zidovuduine therapy. J. Infect. Dis. 158: 489–490.PubMedGoogle Scholar
  195. Jacquez, J.A., J.S. Koopman, C.P. Simon & I.M. Longini Jr., 1994. Role of the primary infection in epidemies of HIV infection in gay cohorts. J. Acquired Immune Deficiency Syndromes 7(11): 1169–1184.Google Scholar
  196. Jaffe, H.W., K. Choi, P.A. Thomas et al., 1983. National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part 1, Epidemiologic results. Ann. Intern. Med. 99(2): 145–151.PubMedGoogle Scholar
  197. Jonnes, J., 1996. Hep-cats, nares, and pipe dreams. Seribner, New York.Google Scholar
  198. Kaposi, M., 1872. Idiopathisches multiples Pigmentsarkom der Haut. Archiv für Dermatologie und Syphilis 2: 265–273.Google Scholar
  199. Karpas, A., S. Ash & D. Bainbridge, 1997. Are anti-HIV drugs an effective treatment? Nature Medicine 3(10): 1052.PubMedGoogle Scholar
  200. Kaslow, R.A., W.C. Blackwelder, D.G. Ostrow, D. Yerg, J. Palenicek, A.H. Coulson & R.O. Valdiserri, 1989. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1-positive individuals. J. Am. Med. Assoc. 261: 3424–3429.Google Scholar
  201. Klimas, N.G., N.T. Blaney, R.O. Morgan, D. Chitwood, K. Milles, H. Lee & M.A. Fletcher, 1991. Immune function and Anti-HTLV-I/II status in Anti-HIV-1-Negative intravenous drug users receiving methadone. The American Journal of Medicine 90 (February): 163–170.Google Scholar
  202. Kline, M.W., R.B. Van Dyke, J.C. Lindsey et al., 1998. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDU, AZT) in children with human immunodeficiency virus infection. Pediatrics 101(2): 214–220.PubMedGoogle Scholar
  203. Koch, T., 1990. Uninfected children of HIV-infected mothers may still suffer nervous problems. CDC AIDS Weekly, July 30, p. 9.Google Scholar
  204. Kolata, G., 1987. Imminent marketing of AZT raises problems; Marrow suppression hampers AZT use in AIDS victims. Science 235: 1462–1463.PubMedGoogle Scholar
  205. Kolata, G., 1995. New picture of who will get AIDS is dominated by addicts. New York Times, February 28, p. 3, Sect. C.Google Scholar
  206. Kozel, N.J. & E.H. Adams, 1986. Epidemiology of drug abuse: An overview. Science 234: 970–974.PubMedGoogle Scholar
  207. Kramer, L., 1994. Checking in, my chart. POZ, August/September, p. 92–93.Google Scholar
  208. Kramer, L., 1996. A good news/bad news AIDS joke. New York Times, Sunday, July 14, p. 26.Google Scholar
  209. Krieger, L., 1996. 1 in 300 U.S. adults infected, says report. San Francisco Examiner, July 7, p. A8.Google Scholar
  210. Krieger, L.M., 1997. AIDS drug cocktails fail 53% in study. San Francisco Examiner, September 29, p. 1, A10.Google Scholar
  211. Krieger, T. & C.A. Caceres, 1985. Wall Street Journal, October 24, p.Google Scholar
  212. Kumar, R.M., P.F. Hughes & A. Khurranna, 1994. Zidovudine Use in Pregnancy: A Report on 104 Cases and the Occurence of Birth Defects. Journal of Acquired Immune Deficiency Syndromes 7(10): 1034–1039.PubMedGoogle Scholar
  213. Lang, S., 1996. To fund or not to fund, that is the question: proposed experiments on the drug-AIDS hypothesis. To inform or not to inform, that is another question, pp. 297–307 in AIDS: Virus or Drug-Induced?, edited by P.H. Duesberg. Kluwer, Dordrecht, The Netherlands.Google Scholar
  214. Lang, S., 1998. Challenges. Springer, New York.Google Scholar
  215. Larrat, P.E. & S. Zierler, 1993. Entangled epidemies: cocaine use and HIV disease. J Psychoactive drugs 25(3): 207–221.PubMedGoogle Scholar
  216. Lauritsen, J., 1990. Poison by Prescription — The AZT Story. Asklepios Press, New York.Google Scholar
  217. Lauritsen, J., 1992. FDA documents show fraud in AZT trials. New York Native, March 30, p. 20–23.Google Scholar
  218. Lauritsen, J., 1993. The AIDS War. Asklepios (Pagan Press), New York.Google Scholar
  219. Lauritsen, J., 1994. NIH reconsiders nitrites' link to AIDS. Biotechnology 12: 762–763.Google Scholar
  220. Lauritsen, J., 1996. NIDA meeting calls for research into the poppers-Kaposi's sarcoma connection, pp. 325–330 in: AIDS: Virus or Drug-Induced?, edited by P.H. Duesberg. Kluwer Academic Publishers, Dordrecht, The Netherlands.Google Scholar
  221. Lauritsen, J. & H. Wilson, 1986. Death Rush, Poppers and AIDS. Pagan Press, New York.Google Scholar
  222. Lauritsen, J. & I. Young, 1997. The AIDS Cult; essays on the Gay Health Crisis. Asklepios-Pagan Press, Provincetown, MA.Google Scholar
  223. Layon, J., A. Idris, M. Warzynski, R. Sherer, D. Brauner, O. Patch, D. McCulley & P. Orris, 1984. Altered T-lymphocyte subsets in hospitalized intravenous drug abusers. Arch. Intern. Med. 144: 1376–1380.PubMedGoogle Scholar
  224. Lazarou, J., B.H. Pomeranz & P.N. Corey, 1998. Incidence of adverse drug reactions in hospitalized patients. Journal of American Medical Association 279: 863–867.Google Scholar
  225. Learmont, J., B. Tindall, L. Evans, A. Cunningham, P. Cunningham, J. Wells, R. Penny, J. Kaldor & D. A. Cooper, 1992. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 340: 863–867.PubMedGoogle Scholar
  226. Leland, J., 1996. The end of AIDS? Newsweek, December 2, p. 64–73.Google Scholar
  227. Lerner, W.D., 1989. Cocaine abuse and acquired immunodeficiency syndrome: tale of two epidemics. Am. J. Med. 87: 661–663.PubMedGoogle Scholar
  228. Levy, J., 1998. Caution: should we be treating HIV infection early? Lancet 352: 982–983.PubMedGoogle Scholar
  229. Lifschitz, M.H., G.S. Wilson, E.O. Smith & M.M. Desmond, 1983. Fetal and postnatal growth of children born to narcotic-dependent women. J. Pediatr. 102: 686–691.PubMedGoogle Scholar
  230. Lifson, A.R., W.W. Darrow, N.A. Hessol, P.M. O'Malley, J.L. Barnhart, H.W. Jaffe & G.W. Rutherford, 1990. Kaposi's sarcoma in a cohort of homosexual and bisexual men: epidemiology and analysis for cofactors. Am. J. Epidemiol. 131: 221–231.PubMedGoogle Scholar
  231. Lipsky, J.J., 1998. Abnormal fat accumulation in patients with HIV-1 infection. Lancet 351: 847–848.PubMedGoogle Scholar
  232. Lo, J.C.K., 1998. ‘Buffalo hump’ in men with HIV-1 infection. Lancet 351: 867–870.PubMedGoogle Scholar
  233. Lockemann, U., F. Wischhusen, K. Pueschel & (over 20 authors), 1995. Vergleich der HIV-1-Praevalenz bei Drogentodesfaelien in Deutschland sowie in verschiedenen europaeischen Grosstaedten (Stand: 31. 12. 1993). AIDS Forschung 10: 253–256.Google Scholar
  234. Los Angeles Times, 1998. Clinton to announce new drug plan. San Francisco Chronicle, February 13, p. A17.Google Scholar
  235. Louria, D.B., 1974. Infectious complications of nonalcoholic drug abuse. Annu. Rev. Med. 25: 219–231.PubMedGoogle Scholar
  236. Luzuriaga, K., Y. Bryson, P. Krogstad, J. Robinson, B. Stechenberg, M. Lamson, S. Cort & J.L. Sullivan, 1997. Combination treatment with zidovudine, didiadenosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N. Engl. J. Med. 336: 1343–9.PubMedGoogle Scholar
  237. Lyles, C.M., J.B. Margolick, J. Astemborski, N.M. Graham, J.C. Anthony, D.R. Hoover & D. Vlahov, 1997. The influence of drug use patterns on the rate of CD4+ lymphocyte decline among HIV-1-infected injecting drug users, AIDS 11(10): 1255–1262.PubMedGoogle Scholar
  238. Maddox, J., 1992. Rage and confusion hide role of HIV. Nature (London) 357: 188–189.Google Scholar
  239. Maddox, J., 1993. Has Duesberg a right of reply? Nature (London) 363: 109.Google Scholar
  240. Maddox, J., 1995. More conviction on HIV and AIDS. Nature (London) 377: 1.Google Scholar
  241. Mann, C., 1995. Poppers... high time to think again. Continuum (London, UK) 3(3): 10.Google Scholar
  242. Mann, J., J. Chin, P. Piot & T. Quinn, 1988. The international epidemiology of AIDS. Sci. Am., p. 82–89.Google Scholar
  243. Marmor, M., A.E. Friedman-Kien, L. Laubenstein, R.D. Byrum, D.C. William, S. D'Onofrio & N. Dubin, 1982. Risk factors for Kaposi's sarcoma in homosexual men. Lancet i: 1083–1087.Google Scholar
  244. Marquart, K.-H., R. Engst & G. Oehlschlaegel, 1991. An 8-year history of Kaposi's sarcoma in an HIV-negative bisexual man. AIDS 5(3): 346–348.Google Scholar
  245. Martinez, M., 1997. The existence of human immunodeficiency virus resistance to nucleoside-analog drugs has not been shown. Med. Hypotheses 49: 235–240.PubMedGoogle Scholar
  246. Mathur-Wagh, U., R.W. Enlow, I. Spigland et al., 1984. Longitudinal study of persistent generalized lymphadenopathy in homosexual men: Relation to acquired immunodeficiency syndrome. Lancet i: 1033–1038.Google Scholar
  247. Mathur-Wagh, U., D. Mildvan & R.T. Senie, 1985. Follow-up of 4 1/2 years on homosexual men with generalized lymphadenopathy. N. Engl. J. Med. 313: 1542–1543.PubMedGoogle Scholar
  248. Maugh II, T.H., 1998. Researchers on path to first inexpensive AIDS medication. San Francisco Chronicle, February 6, p. A6.Google Scholar
  249. McDonough, R.J., J.J. Madden, A. Falek, D.A. Shafer, M. Pline, D. Gordon, P. Bokof, J.C. Kuehnle & J. Mandelson, 1980. Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence of opiate receptor sites on T lymphocytes. J. Immunol. 125: 2539–2543.PubMedGoogle Scholar
  250. McEvoy, A. W., N.D. Kitchen & D.G.T. Thomas, 1998. Intracerebral haemorrhage caused by drug abuse. Lancet 351: 1029.PubMedGoogle Scholar
  251. McLeod, G.X. & S.M. Hammer, 1992. Zidovudine: Five years later. Ann. Intern. Med. 117(6): 487–501.PubMedGoogle Scholar
  252. McManus, T.J., L.A. Starrett & J.R.W. Harris, 1982. Amyl Nitrite use by homosexuals. Lancet i (February 27): 503.Google Scholar
  253. Meduri, G.U., D.E. Stover, M. Lee, P.L. Myskowski, J.F. Caravelli & M.B. Zama, 1986. Pulmonary Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical, radiographic, and pathologic manifestations. Am. J. Med. 81: 11–18.PubMedGoogle Scholar
  254. Merck & Co., 1997. Crixivan (Indinavir sulfate): patient information about Crixivan. SPIN, June, 1997, p111–114.Google Scholar
  255. Merck Research Laboratories, 1992. The Merck Manual of Diagnosis and Therapy. Merck & Co., Inc., Rahway, NJ.Google Scholar
  256. Merriam-Webster (eds), 1965. Webster's Third International Dictionary. G. & C. Merriam Co., Springfield, MA.Google Scholar
  257. Merson, M.H., 1993. Slowing the spread of HIV: Agenda for the 1990s. Science 260: 1266–1268.PubMedGoogle Scholar
  258. Mientjes, G.H., F. Miedema, E.J. van Ameijden, A.A. van den Hoek, P.T.A. Schellekens, M.T. Roos & R.A. Coutinho, 1991. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS 5: 35–41.PubMedGoogle Scholar
  259. Mientjes, G.H.C., E.J.C. van Ameijden, H.M. Weigel, J.A.R. van den Hoek & R.A. Countinho, 1993. Clinical symptoms associated with seroconversion for HIV-1 among misusers of intravenous drugs: comparison with homosexual seroconverters and infected and non-infected intravenous drug misusers. Br. Med. J 306: 371–373.Google Scholar
  260. Miller, K.D., E. Jones, J.A. Yanovski, R. Shankar, I. Feuerstein & J. Falloon, 1998. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351: 871–875.PubMedGoogle Scholar
  261. Mills, J. & H. Masur, 1990. AIDS-related infections. Sci. Am. 263(2): 50–57.PubMedGoogle Scholar
  262. Mims, C. & D.O. White, 1984. Viral Pathogenesis and Immunology. Blackwell Scientific Publications, Oxford.Google Scholar
  263. Mirken, B., 1995. Everything you always wanted to know about poppers; the ‘gay drug’ is still here despite a ban, and so is the controversy. San Francisco Frontiers Newsmagazine, July 20, p. 16–19.Google Scholar
  264. Moberg, C.L. & Z.A. Cohn, 1991. Rene Jules Dubos. Sci. Am. 264(5): 66–74.PubMedGoogle Scholar
  265. Mok, J.Q., A. De Rossi, A.E. Ades, C. Giaquinto, I. Grosch-Woerner & C.S. Peckham, 1987. Infants born to mothers seropositive for human immunodeficiency virus. Lancet i: 1164–1168.Google Scholar
  266. Moss, A.R., 1987. AIDS and intravenous drug use: the real heterosexual epidemic. Br. Med. J. 294: 389–390.Google Scholar
  267. Moye, J., K.C. Rich, L.A. Kalish, A.R. Sheon, C. Diaz, E.R. Cooper, J. Pitt, E. Handelsman & for the Women and Infants Transmission Study Group, 1996. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. The Journal of Pediatrics 128(1): 58–67.PubMedGoogle Scholar
  268. Mullis, K., 1996. Foreword, pp. XI–XIV in Inventing the AIDS Virus, edited by P. Duesberg. Regnery Publishing, Inc., Washington, DC.Google Scholar
  269. Mullis, K.B., 1995. A hypothetical disease of the immune system that may bear some relation to the Acquired Immune Deficiency Syndrome. Genetica 95(1–3): 195–197.PubMedGoogle Scholar
  270. Muñoz, A., D. Vlahov, L. Solomon, J.B. Margolick, J.C. Bareta, S. Cohn, J. Astemborski & K.E. Nelson, 1992. Prognostic indicators for development of AIDS among intranvenous drug users. J. Acquir. Immune Defic. Syndr. 5: 694–700.PubMedGoogle Scholar
  271. Murray, H.W., D.A. Scavuzzo, C.D. Kelly, B.Y. Rubin & R.B. Roberts, 1988. T4+ cell production of interferon gamma and the clinical spectrum of patients at risk for and with acquired immunodeficiency syndrome. Arch. Intern. Med. 148: 1613–1616.PubMedGoogle Scholar
  272. National Commission on AIDS, July 1991. The Twin Epidemics of Substance Use and HIV. National Commission on AIDS.Google Scholar
  273. National Research Council, 1982. Diet, nutrition, and cancer. National Acad. Press, Washington, DC.Google Scholar
  274. New York Times, 1997. Most $1 bills tainted by cocaine, lab finds. The New York Times, September 23.Google Scholar
  275. Newell, G.R., S.C. Adamas, P.W.A. Mansell & E.M. Hersh, 1984. Toxicity, immunosupprressive effects, and carcinogenic potential of volatile nitrites: possible relationship to Kaposi's sarcoma. Pharmacotherapy 4: 284–291.PubMedGoogle Scholar
  276. Newell, G.R., P.W.A. Mansell, M.R. Spitz, J.M. Reuben & E.M. Hersh, 1985a. Volatile nitrites: Use and adverse effects related to the current epidemic of the acquired immune deficiency syndrome. Am. J. Med. 78: 811–816.PubMedGoogle Scholar
  277. Newell, G.R., P.W.A. Mansell, M.B. Wilson, H.K. Lynch, M.R. Spitz & E.M. Hersh, 1985b. Risk factor analysis among men referred for possible acquired immune deficiency syndrome. Preventive Med. 14: 81–91.Google Scholar
  278. Nieman, R.B., J. Fleming, R.J. Coker, J.R. Harris & D.M. Mitchell, 1993. The effect of cigarette smoking on the development of AIDS in HIV-1-seropositive individuals. AIDS 7: 705–710.PubMedGoogle Scholar
  279. Novick, D.M., M. Ochshorn, V. Ghali, T.S. Croxson, W.D. Mercer, N. Chiorazzi & M.J. Kreek, 1989. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadonc maintenance patients. The Journal of Pharmacology and Experimental Therapeutics 250(2): 606–610.PubMedGoogle Scholar
  280. Nussbaum, B., 1990. Good Intentions: How Big Business, Politics, and Medicine are Corrupting the Fight Against AIDS. Atlantic Monthly Press, New York.Google Scholar
  281. O'Brien, S.J., 1997. The HIV-AIDS debate is over. HIV Newsline 4: 3–9.Google Scholar
  282. O'Brien, S.J. & J.J. Goedert, 1996. HIV causes AIDS: Koch's postulates fulfilled. Current Opinion in Immunology 8: 613–618.PubMedGoogle Scholar
  283. Office of National Drug Control Policy, 1996. Drugs & Crime Data. Drugs & Crime Clearinghouse, July 1996.Google Scholar
  284. Olivero, O.A., L.M. Anderson, B.A. Diwan et al., 1997. Transplacental effects of 3′-azido-2′, 3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J. Natl. Cancer Inst. 89: 1602–1608.PubMedGoogle Scholar
  285. Omar, R.F., P. Gourde, A. Desormeaux, M. Tremblay, D. Beauchamp & M.G. Bergeron, 1996. In vivo toxicity of foscarnet and zidovudine given alone or in combination. Toxicol. Appl. Pharmacol. 139: 324–332.PubMedGoogle Scholar
  286. Oppenheimer, G.M., 1992. Causes, cases, and cohorts: The role of epidemiology in the historical construction of AIDS, pp. 49–83 in AIDS: The Making of a Chronic Disease, edited by E. Fee & D.M. Fox. University of California Press, Berkeley, California.Google Scholar
  287. Ostrow, D.G., 1994. Substance abuse and HIV infection. Psychiatric Manifestations of HIV Disease 17(1): 69–89.Google Scholar
  288. Ostrow, D.G., E.D. Beltran, J.G. Joseph, W. DiFranceisco, J. Wesch & J.S. Chmiel, 1993. Recreational drugs and sexual behavior in the Chicago MACS/CCS cohort of homosexually active men. J. Subst. Abuse 5: 311–325.PubMedGoogle Scholar
  289. Ostrow, D.G., M.J. Van Raden, R. Fox, L.A. Kingsley, J. Dudley, R.A. Kaslow & the Multicenter AIDS Cohort Study (MACS), 1990. Recreational drug use and sexual behavior change in a cohort of homosexual men. AIDS 4(8): 759–765.PubMedGoogle Scholar
  290. Padian, N.S., S.C. Shiboski, S.O. Glass & E. Vittinghoff, 1997. Heterosexual transmission of human immunodeficiency virus (HIV) in Northern California: results from a ten-year study. Am. J. Epidemiol. 146: 350–357.PubMedGoogle Scholar
  291. Parker, S.L., T. Tong, S. Bolden & P.A. Wingo, 1996. Cancer statistics, 1996. CA Cancer J Clin 46: 5–27.PubMedGoogle Scholar
  292. Parker, W.B. & Y.C. Cheng, 1994. Mitochondrial Toxicity of Antiviral Nucleoside Analogs. The Journal of NIH Research 6 (March): 57–61.Google Scholar
  293. Pellegrino, T. & B.M. Bayer, 1998. In vivo effects of cocaine on immune cell function. J Neuroimmunol 83(1–2): 139–147.PubMedGoogle Scholar
  294. Pennisi, E. & J. Cohen, 1996. Eradicating HIV from a patient: not just a dream? Science 272: 1884.PubMedGoogle Scholar
  295. Perlman, D., 1998. Quarter of AIDS patients not getting best therapy. San Francisco Chronicle, Thursday, June 4, 1998, p. A9.Google Scholar
  296. Peterman, T.A., R.L. Stonebumer, J.R. Allen, H.W. Jaffe & J.W. Curran, 1988. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. J. Am. Med. Assoc. 259: 55–58.Google Scholar
  297. Phillips, A.N. & G.D. Smith, 1997. Viral load and combination therapy for human immunodeficiency virus. N. Engl. J. Med. 336(13): 958–959.PubMedGoogle Scholar
  298. Physician's Desk Reference, 1997. Invirase. In: M. E. Co. (eds.). Montvale, NJ.Google Scholar
  299. Pillai, R., B.S. Nair & R.R. Watson, 1991. AIDS, drugs of abuse and the immune system: a complex immunotoxicological network. Arch. Toxicol. 65: 609–617.PubMedGoogle Scholar
  300. Pillari, G. & J. Narus, 1973. Physical effects of heroin addiction. Am. J. Nursing 73: 2105–2109.Google Scholar
  301. Pink Paper, 1996. Shops on their guard after poppers sale legal setback. The Pink Paper, London, UK June 28Google Scholar
  302. Pitot, H.C., 1986. Fundamentals of Oncology. Marcel Dekker, Inc., New York.Google Scholar
  303. Pluda, J.M., R. Yarchoan, E.S. Jaffe et al., 1990. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann. Intern. Med. 113(4): 276–282.PubMedGoogle Scholar
  304. Potts, M., 1995. Non-surgical abortion: who's for methotrexate. Lancet 346 (September 9): 655–656.Google Scholar
  305. Poznansky, M.C., R. Coker, C. Skinner, A. Hill, S. Bailey, L. Whitaker, A. Renton & J. Weber, 1995. HIV positive patients first presenting with an AIDS defining illness: characteristics and survival. Br. Med. J. 311: 156–158.Google Scholar
  306. Race, E.M., J. Adelson-Mitty, G.R. Kriegel, T.F. Barlam, K.A. Reimann, N.L. Letvin & A.J. Japour, 1998. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 351 (January 24): 252–255.Google Scholar
  307. Rappoport, J., 1988. AIDS INC. Human Energy Press, San Bruno, CA.Google Scholar
  308. Ratajczak, H.V., P.T. Thomas, R.V. House et al., 1995. Local versus Systemic Immunotoxicity of Isobutyl Nitrite Following Subchronic Inhalation Exposure of Female B6C3F1 Micc. Fundamental and Applied Toxicology 27: 177–184.PubMedGoogle Scholar
  309. Retrovir, 1994. Physicians' Desk Reference. Medical Economics Co., Orandell, NJ.Google Scholar
  310. Richman, D.D., M.A. Fischl, M.H. Grieco et al., 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 317: 192–197.PubMedGoogle Scholar
  311. Rodriguez, E.M., L.M. Mofenson, B.-H. Chang et al., 1996. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. AIDS 10: 273–282.PubMedGoogle Scholar
  312. Roederer, M., 1998. Getting to the HAART of T cell dynamics. Nature Medicine 4(2): 145–146.PubMedGoogle Scholar
  313. Rogers, M.F., C.-Y. Ou, M. Rayfield et al., 1989. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. N. Engl. J. Med. 320: 1649–1654.PubMedGoogle Scholar
  314. Root-Bernstein, R., 1993. The tragic cost of premature consensus. Free Press, New York, NY.Google Scholar
  315. Rotello, G., 1996. A deal with the devil. The Advocate, October, 15, p. 96.Google Scholar
  316. Russel, S., 1998. AIDS deaths drop 60% in California. San Francisco Chronicle, January 9, p. 1, A12.Google Scholar
  317. Russell, S., 1996. "speed’ Hospitalizations Soar. San Francisco Chronicle, July 2, p. A13, A15.Google Scholar
  318. Saah, A.J., D.R. Hoover, Y. Peng, J.P. Phair, B. Visscher, L.A. Kingsley, L.K. Schrager & for the Multicenter AIDS Cohort Study, 1995. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. J. Am. Med. Assoc. 273: 1197–1202.Google Scholar
  319. Sabin, C.A., A.N. Phillips & C.A. Lee, 1996. Response: arguments contradict the ‘foreign protein-zidovudine’ hypothesis. Br. Med. J. 312: 211–212.Google Scholar
  320. Sadownick, D., 1994. Kneeling at the Crystal Cathedral. Genre, December/January 1994, p. 40–45, 86–90.Google Scholar
  321. Safai, B., H. Peralta, K. Menzies, H. Tizon, P. Roy, N. Flomberg & S. Wolinsky (1991) Kaposi's sarcoma among HIV-negative high risk population. VII International Conference on AIDS, Florence, Italy.Google Scholar
  322. San Francisco Department of Public Health & Lesbian & Gay Substance Abuse Planning Group, 1991. Lesbian, Gay and Bisexual Substance Abuse Needs Assessment. San Francisco Department of Public Health.Google Scholar
  323. Sapira, J.D., 1968. The narcotic addict as a medical patient. Am. J. Med. 45: 555–588.PubMedGoogle Scholar
  324. Savona, S., M.A. Nardi, E.T. Lenette & S. Karpatkin, 1985. Thrombocytopenic purpura in narcotics addicts. Ann. Intern. Med. 102(6): 737–741.PubMedGoogle Scholar
  325. Schechter, M.T., K.J.P. Craib, K.A. Gelmon, J.S.G. Montaner, T.N. Le & M.V. O'Shaughnessy, 1993a. HIV-1 and the aetiology of AIDS. Lancet 341: 658–659.PubMedGoogle Scholar
  326. Schechter, M.T., K.J.P. Craib, K.A. Gelmon, J.S.G. Montaner, T.N. Le & M.V. O'Shaughnessy, 1993b. HIV-1 and the aetiology of AIDS. Lancet 341: 658–659.PubMedGoogle Scholar
  327. Schechter, M.T., K.J.P. Craib, J.S.G. Montaner, T.N. Le, M.V. O'Shaughnessy & K.A. Gelmon, 1993c. Actiology of AIDS. Lancet 341: 1222–1223.PubMedGoogle Scholar
  328. Schnoll, S.H., J. Karrigan, S.B. Kitchen, A. Daghestani & T. Hansen, 1985. Characteristics of coeaine abusers presenting for treatment, pp. 171–181 in Cocaine use in America: epidemiologic and clinical perspectives, 61, edited by NIDA US Dept. HHS. US Department of Health & Human Services.Google Scholar
  329. Schuster, C., 1985. Coeaine use in America: epidemiological and clinical perspectives p. v in NIDA Research Monograph Series, 61, edited by NIDA US Department HHS. US Department of Health & Human Services.Google Scholar
  330. Scolaro, M., R. Durham & G. Pieczenik, 1991. Potential molecular competitor for HIV. Lancet 337: 731–732.PubMedGoogle Scholar
  331. Seligmann, M., L. Chess, J.L. Fahey et al., 1984. AIDS — an immunologic reevaluation. N. Engl. J. Med. 311: 1286–1292.PubMedGoogle Scholar
  332. Seligmann, M., D.A. Warrell, J.-P. Aboulker et al., 1994. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343: 871–881.Google Scholar
  333. Selik, R.M., H.W. Haverkos & J.W. Curran, 1984. Acquired Immune Deficiency Syndrome (AIDS) in the United States, 1978–1982. American Journal of Medicine 76 (March): 493–500.Google Scholar
  334. Selik, R.M., E.T. Starcher & J.W. Curran, 1987. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS 1: 175–182.PubMedGoogle Scholar
  335. Selwyn, P.A., A.R. Feingold, D. Hartel, E.E. Schoenbaum, M.H. Adderman, R.S. Klein & S.H. Freidland, 1988. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 2: 267–272.PubMedGoogle Scholar
  336. Shenton, J., 1998. Positively False: exposing the myths around HIV and AIDS. I.B. Tauris, London/New York.Google Scholar
  337. Shilts, R., 1987. And the Band Played On. St. Martin's Press, New York.Google Scholar
  338. Signorile, M., 1997a. The ineredible bulk: If looks like the whole gay world is on steroids, maybe that's because it is. Out, May, p70, 72, 73, 124.Google Scholar
  339. Signorile, M., 1997b. Life Outside: The Signorile report on Gay Men: Sex, Drugs, Muscles, and the Passages of Life. Harper-Collins Publishers, New York.Google Scholar
  340. Simmons, T., 1995. Living on the edge. The Advocate, December 26, p. 25–28.Google Scholar
  341. Sloand, E., P.N. Kumar & P.F. Pierce, 1993. Chemotherapy for patients with pulmonary Kaposi's sarcoma: benefit of filgrastim (G-CSF) in supporting dose administration. Southern Medical Journal 86: 1219–1224.PubMedGoogle Scholar
  342. Smothers, K., 1991. Pharmacology and toxicology of AIDS therapies. The AIDS Reader 1(1): 29–35.Google Scholar
  343. Soderberg, L.S., 1998. Immunomodulation by nitrite inhalants may predispose abusers to AIDS and Kaposi's sarcoma. J. Neuroimmunol. 83: 157–161.PubMedGoogle Scholar
  344. Sonnabend, J.A., S.S. Witkin & D.T. Purtillo, 1983. A multifactorial model for the development of AIDS in homosexual men. Ann. N.Y. Acad. Sci. 437: 177–183.Google Scholar
  345. Spornraft, P., M. Froschl, J. Ring, M. Meurer, F.D. Goebel, H.W. Ziegler-Heitbrock, G. Riethmuller & O. Braun-Falco, 1988. T4/T8 ratio and absolute T4 cell numbers in different clinical stages of Kaposi's sarcoma in AIDS. Br. J. Dermatol. 119(1): 1–9.PubMedGoogle Scholar
  346. Springer Verlag, 1996, 46–96; 50 Jahre Springer — 50 Jahre Zeitzeuge, Axel Springer Verlag, Hamburg, Germany.Google Scholar
  347. St. Angelo, M., 1996. Duesberg's Questions About HIV/AIDS Merit Answers. Windy City Times, April 11, p. 12.Google Scholar
  348. Stewart, G.T., 1968. Limitations of the germ theory. Lancet i: 1077–1081.Google Scholar
  349. Stewart, G.T., 1989. Uncertainties about AIDS and HIV. Lancet i: 1325.Google Scholar
  350. Stewart, G.T., 1996. The epidemiology and transmission of AIDS: a hypothesis linking behavioural and biological determinants to time, person and place pp. 163–183 in AIDS: Virus or Drug-Induced?, vol. 5, edited by P.H. Duesberg. Kluwer Academic Publishers, Dordrecht, The Netherlands.Google Scholar
  351. Stolberg, S.G., 1997. Despite new AIDS drugs, many still lose the battle. The New York Times, August 22, p. 1, A6.Google Scholar
  352. Stoneburner, R.L., D.C. Des Jarlais, D. Benezra et al., 1988. A larger spectrum of severe HIV-I-related disease in intravenous drug users in New York City, Science 242: 916–919.PubMedGoogle Scholar
  353. Tanaka, M., 1996. Abrams cautious on use of new AIDS drugs. Synapse (University of California San Francisco), October 10, p. 1, 5.Google Scholar
  354. Terry, C.E. & M. Pellens, 1928. The Opium Problem. Bureau of Social Hygiene of New York.Google Scholar
  355. The European Collaborative Study, 1994. Natural History of Vertically Acquired Human Immunodeficiency Virus-1 Infection. Pediatrics 94(6): 815–819.Google Scholar
  356. The Lancet, 1994. Zidovudine for mother, fetus, and child: hope or poison? Lancet 344(8917): 207–209.Google Scholar
  357. Thompson, M.B., J.K. Dunnick, M.E. Sutphin, H.D. Giles, R.D. Irwin & J.D. Prejean, 1991. Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice. Fundamental and Applied Toxicology 17: 159–176.PubMedGoogle Scholar
  358. Till, M. & K.B. MacDonnell, 1990. Myopathy with human immunodeficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine? Ann. Intern. Med. 113: 492–494.PubMedGoogle Scholar
  359. Toltzis, P., T. Mourton & T. Magnuson, 1993. Effect of zidovudine on preimplantation murine embryos. Antimicrob. Agents Chemother. 37: 1610–1613.PubMedGoogle Scholar
  360. Toufexis, A., 1991. Innocent victims. Time, May 13, p. 56–60.Google Scholar
  361. Tubaro, E., G. Borelli, C. Croce, G. Cavallo & C. Santiangeli, 1983. Effect of morphine on resistance to infection. J. Infect. Dis. 148(4): 656–666.PubMedGoogle Scholar
  362. Tuller, D., 1996. Uncertain life after certain death. San Francisco Chronicle, November 24, p. 1–5 zone 6.Google Scholar
  363. U.S. Department of Health & Human Services, 1993. Annual emergency department data 1993. Data from the Drug Abuse Warning Network (DAWN), p. 81–110.Google Scholar
  364. U.S. Department of Health & Human Services, 1994. Annual Medical Examiner data. Data from the Drug Abuse Warning Network (DAWN), 1994, p. 1–82.Google Scholar
  365. US Department of Health & Human Services & Public Health Service & Substance Abuse and Mental Health Services Administration (SAMHSA), 1996. Historical estimates from the drug abuse warning network.Google Scholar
  366. Veugelers, P.J., K.A. Page, B. Tindall et al., 1994. Determinants of HIV disease progression among homsexual men registered in the tricontinental seroconverter study. Am. J. Epidemiol. 140(8): 747–758.PubMedGoogle Scholar
  367. Volkow, N.D., G.-J. Wang, M.W. Fischmann, R.W. Foltin, J.S. Fowler, N.N. Abumrad, R. Hitzemann & C.E. Shea, 1997. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature (London) 386: 827–830.Google Scholar
  368. Wallace, B., 1996. "speed’ Abusers Need More and More. San Francisco Chronicle, May 31, p. A2.Google Scholar
  369. Ward, J.W., T.J. Bush, H.A. Perkins et al., 1989. The natural history of transfusion-associated infection with human immunodeficiency virus. N. Engl. J. Med. 321: 947–952.PubMedGoogle Scholar
  370. Weber, R., W. Ledergerber, M. Opravil, W. Siegenthaler & R. Lüthy, 1990. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. Br. Med. J. 301: 1362–1365.Google Scholar
  371. Weil, A. & W. Rosen, 1983. Chocolate and morphine. Houghton Mifflin Co., Boston.Google Scholar
  372. Weiss, R., 1991. Provenance of HIV strains. Nature (London) 349: 374.Google Scholar
  373. Weiss, R. & H. Jaffe, 1990. Duesberg, HIV and AIDS. Nature (London) 345: 659–660.Google Scholar
  374. Wesson, D. & D. Smith, 1985. Cocaine: treatment perspectives, in Cocaine Use in America: epidemiologic and clinical perspectives, 61, edited by N. Kozel & E. Adams. NIDA, US Dept. HHS. Washington, DC.Google Scholar
  375. White House Office of National Drug Control Policy, 1998. Fact Sheet: Drug data summary. DHSS, the White House.Google Scholar
  376. Whitehead, A.N., 1967. Science and the Modern World. p. 187, The Free Press, a division of Macmillan Publishing Co., Inc., New York.Google Scholar
  377. Wilson, J.M., K.S. Kalasinsky, A.I. Levey et al., 1996. Striatal dopamine nerve terminal markers in human, chronic metamphetamine users. Nature Medicine 2(6): 699–703.PubMedGoogle Scholar
  378. World Health Organisation, 1996. WHO Report No 48. Weekly Epidemiological Record (WER) 48(71): 361–368.Google Scholar
  379. World Health Organization, 1995a. The Current Global Situation of the HIV/AIDS Pandemic. WHO.Google Scholar
  380. World Health Organization, 1995b. WHO Report No. 45: AIDS Surveillance in Europe. AIDS Forschung 10: 603–613.Google Scholar
  381. Yarchoan, R. & S. Broder, 1987. Antiretroviral therapy for AIDS. N. Engl. J. Med. 317: 630.Google Scholar
  382. Yarchoan, R., J.M. Pluda, C.-F. Perno, H. Mitsuya & S. Broder, 1991. Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood 78: 859–884.PubMedGoogle Scholar
  383. Young, I., 1995. Hell Bent... or Heavenly Scent? Continuum, p. 22–25.Google Scholar
  384. Zachary, B., 1997. Confronting the crystal culture crisis. San Francisco Frontiers, July 31.Google Scholar
  385. Zonona, V., 1992. Kramer vs. the World (interview with Larry Kramer). The Advocate, December 1.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Peter Duesberg
    • 1
  • David Rasnick
    • 1
  1. 1.Department of Molecular and Cell BiologyStanley Hall, UC BerkeleyBerkeleyUSA (Phone

Personalised recommendations